Product Description
Anti-PD-L1 Antibody for HIV infection (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02028403)
Mechanisms of Action: PD-L1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|HIV Infections|Melanoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Multiple Myeloma|Lymphoma, Non-Hodgkin|Shock, Septic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Anti-PDL1 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2015-07-01 |
|
| CA210-003 | P1 |
Withdrawn |
Multiple Myeloma|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma, Non-Hodgkin |
2014-11-01 |
|
| PD-L1 | P1 |
Withdrawn |
Melanoma |
2013-11-01 |
|
| A5326 | P1 |
Completed |
HIV Infections |
2015-11-01 |
|
| AI471-049 | P1 |
Terminated |
Shock, Septic |
2017-03-15 |